( NASDAQ-NMS:SGMO )

News from Sangamo Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 07, 2017, 16:22 ET Sangamo Announces European Medicines Agency Recommendation Of Orphan Medicinal Product Designation For Investigational Genome Editing Treatments For MPS I And MPS II

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA)...


Nov 24, 2017, 13:01 ET Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced today that the Compensation Committee of the Company's Board of Directors approved the grant...


Nov 15, 2017, 01:10 ET Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study")...


Nov 09, 2017, 16:01 ET Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical Operations

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced a strategic investment in manufacturing, including an expanded commitment with Brammer...


Nov 09, 2017, 16:01 ET Sangamo Therapeutics Reports Third Quarter 2017 Financial Results

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its third quarter 2017 financial results and recent accomplishments. "We continue to make...


Nov 09, 2017, 16:01 ET Sangamo Announces Plans For New Headquarters In Brisbane, California

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced plans for new corporate headquarters at 7000 Marina Boulevard, an 88,000 square foot...


Oct 31, 2017, 16:01 ET Sangamo Therapeutics Announces Third Quarter 2017 Conference Call And Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its third quarter 2017 financial results after the market...


Oct 17, 2017, 16:05 ET Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today presentations by Company scientists at the 2017 Annual Congress of the European Society of...


Oct 02, 2017, 07:30 ET Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical...


Sep 28, 2017, 16:01 ET Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will...


Sep 20, 2017, 16:01 ET Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

RICHMOND, Calif., Sept. 20, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D.,...


Aug 31, 2017, 16:01 ET Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit

Sangamo Therapeutics (Nasdaq: SGMO) this afternoon is presenting preclinical data demonstrating the Company's engineering capabilities in T cell...


Aug 30, 2017, 16:01 ET Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that members of the Company's senior management team are scheduled to participate in the...


Aug 25, 2017, 08:00 ET Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced that the first patient received treatment in the Phase 1/2...


Aug 10, 2017, 16:01 ET Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will...


Aug 09, 2017, 16:01 ET Sangamo Therapeutics Reports Second Quarter 2017 Financial Results

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported its second quarter 2017 financial results and recent accomplishments. "In the second...


Aug 02, 2017, 16:01 ET Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its second quarter 2017 financial results after the market...


Jul 13, 2017, 16:01 ET Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...


Jun 29, 2017, 16:01 ET Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to the Company's Board of...


Jun 26, 2017, 16:05 ET Sangamo Therapeutics Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the closing of its public offering of 10,000,000 shares of common stock at a price to the...


Jun 21, 2017, 08:26 ET Sangamo Therapeutics Announces Pricing Of $72.5 Million Public Offering Of Common Stock

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock...


Jun 20, 2017, 16:01 ET Sangamo Therapeutics Announces Proposed Public Offering of Common Stock

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that it has commenced an underwritten public offering of shares of its common stock. All...


Jun 07, 2017, 07:30 ET Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) and Pfizer Inc. (NYSE: PFE) announced today that the European Medicines Agency (EMA) has granted orphan...


Jun 02, 2017, 16:01 ET Sangamo Therapeutics Announces Presentation At The Jefferies 2017 Global Healthcare Conference

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D.,...


May 16, 2017, 07:30 ET Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...